China: NMPA and the restructuring of the pharmaceutical inspection system

China’s pharmaceutical inspection framework has undergone a fundamental transformation since 2019. The cancellation of separate GMP certification, nationwide implementation of the marketing authorisation holder (MAH) system and redistribution of inspection responsibilities have changed how domestic and foreign manufacturers are supervised. Understanding the roles of the National Medical Products Administration (NMPA), the Center for Drug Evaluation (CDE), the Center for Food and Drug Inspection (CFDI) and provincial authorities is essential for companies operating in or supplying the Chinese market.

The 2019 reform: from certification to continuous supervision

The starting point for understanding China’s current pharmaceutical inspection system is the revised Drug Administration Law (DAL), which entered into force on 1 December 2019.

The reform introduced two major changes.

First, the MAH system was extended nationwide. The holder of a drug marketing authorisation became responsible for the safety, efficacy and quality of the product throughout its lifecycle, covering research and development, manufacturing, distribution and use.

Second, separate drug Good Manufacturing Practice (GMP) and Good Supply Practice (GSP) certification procedures were cancelled.

This did not mean that GMP requirements were relaxed or that inspections became less important. Manufacturing activities remained subject to GMP, while regulatory supervision increasingly relied on manufacturing licences, inspections and continuous oversight of compliance.

The reform shifted the emphasis from obtaining a separate certificate to maintaining compliance throughout the product lifecycle.

Who sets the requirements?

China’s pharmaceutical manufacturing and inspection framework is based on several levels of regulation.

The Drug Administration Law (2019 revision) establishes the legal responsibilities of MAHs, manufacturers and regulatory authorities. It provides the foundation for lifecycle quality management and continuous GMP compliance.

Good Manufacturing Practice (GMP) sets the manufacturing and quality-system requirements. The current general Chinese GMP framework is based on the 2010 revision, which entered into force on 1 March 2011. It contains 14 chapters and 313 articles.

Subordinate regulations define the operational framework. Two particularly important instruments are the Provisions for Drug Registration and the Provisions for the Supervision and Administration of Drug Manufacturing.

International harmonisation is another important part of the framework. NMPA joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) in 2017 and was re-elected to its Management Committee in 2018, 2021 and 2024.

Who inspects: the institutional structure

NMPA: national regulatory authority

The National Medical Products Administration (NMPA) is responsible for nationwide drug regulation, policy development and the overall supervision and guidance of provincial regulatory authorities.

Two technical institutions play particularly important roles in drug review and inspection.

Center for Drug Evaluation (CDE)

CDE is responsible for the technical review of drug registration applications. It assesses, on a risk basis, whether registration inspections are required and initiates the relevant inspection process.

Center for Food and Drug Inspection (CFDI)

CFDI is NMPA’s operational inspection institution. Its responsibilities include organising drug registration inspections, conducting overseas inspections, organising vaccine inspections and developing inspection-related technical standards.

CFDI also analyses inspection risks, prepares inspection conclusions and proposes regulatory handling measures.

Provincial drug regulatory authorities

Drug regulatory authorities at the provincial level — covering provinces, autonomous regions and municipalities directly under the central government — have direct responsibility for pharmaceutical manufacturing supervision within their administrative territories.

Their responsibilities include:

  • issuing drug manufacturing licences;
  • inspecting domestic manufacturing sites;
  • conducting routine and risk-based supervision;
  • supervising domestic MAHs and manufacturers;
  • conducting pre-marketing GMP compliance inspections where required;
  • taking administrative enforcement measures within their jurisdiction.

This division of responsibilities is important: national technical institutions and provincial authorities perform complementary functions rather than operate as interchangeable inspection bodies.

How inspection responsibilities are divided

Grounds and types of inspection

Drug registration inspections

Registration inspections go beyond a conventional GMP audit.

Their purpose is to verify the authenticity and consistency of the information submitted in the registration dossier and to assess whether the research, manufacturing and quality-control activities correspond to the application.

The inspection may cover research and development sites, manufacturing facilities and, where necessary, suppliers or contracted organisations involved in the application.

The CDE determines whether an inspection is required on a risk basis. CFDI organises and conducts the inspection and provides its findings for consideration as part of the registration review.

Under the Provisions for Drug Registration, CFDI should, in principle, complete the manufacturing-site inspection at least 40 days before the end of the applicable review timeline.

This makes inspection readiness an integral part of registration planning rather than a final administrative step.

Collaborative registration and GMP inspections

Where both a drug registration inspection and a pre-marketing GMP compliance inspection are necessary, CFDI coordinates with the relevant provincial authority to conduct the inspections concurrently.

This approach links the assessment of registration-dossier authenticity and manufacturing compliance.

Routine and risk-based supervision

Provincial authorities conduct routine inspections of domestic manufacturers and MAHs.

Inspection frequency and scope are determined through risk assessment, taking into account product characteristics, previous inspection results, safety information and other relevant factors.

The authorities may also extend inspections to suppliers and other organisations involved in pharmaceutical manufacturing.

For-cause and overseas inspections

For-cause inspections may be initiated when concerns arise about the authenticity of registration information, manufacturing activities or compliance.

CFDI is responsible for overseas inspections of foreign pharmaceutical manufacturing sites supplying the Chinese market.

For international manufacturers, this means that regulatory oversight may extend beyond the Chinese MAH or local registration representative to the actual manufacturing facilities abroad.

What is inspected: domestic and foreign manufacturers

Domestic manufacturing sites

Provincial authorities are responsible for manufacturing licences and direct supervision of domestic production.

They also supervise domestic MAHs and manufacturers within their territories. Where the MAH and contract manufacturer are located in different provinces, the relevant authorities have separate responsibilities for the respective entities and may coordinate their inspection activities.

Foreign manufacturers supplying China

Foreign manufacturers are subject to the Chinese registration and inspection framework for imported medicines.

Overseas manufacturing sites may be inspected by CFDI. Foreign marketing authorisation holders must comply with the applicable Chinese registration and representation requirements.

For foreign companies, preparation must therefore cover both the product registration dossier and the inspection readiness of the actual manufacturing site.

APIs, excipients and packaging materials

China applies an associated review and approval framework to active pharmaceutical ingredients (APIs), pharmaceutical excipients and packaging materials and containers that come into direct contact with drugs.

Under the framework introduced in 2019, the associated review status is reflected in the NMPA registration database.

Two statuses are particularly relevant:

  • A — Active: the associated material has passed the technical review in connection with an approved drug application;
  • I — Inactive: the technical review has not been passed or the material has not yet been associated with an approved drug registration application.

These statuses are part of the associated review system and should not be confused with independent marketing authorisation of the finished medicinal product.

APIs with Active status remain subject to applicable post-marketing supervision and GMP requirements, including inspections by provincial authorities.

Foreign suppliers of APIs, excipients and packaging materials must also comply with the applicable registration and representation arrangements in China.

The contract manufacturing chain

The MAH system places significant responsibility on the marketing authorisation holder for outsourced manufacturing.

MAHs must establish quality assurance systems and regularly audit the quality management systems of their contract manufacturers and distributors.

They must also maintain appropriate quality and manufacturing agreements and oversee the performance of contracted organisations.

Consequently, an inspection may examine not only the manufacturing site itself but also the MAH’s oversight of the wider manufacturing and distribution chain.

What inspection outcomes mean

The cancellation of separate GMP certification changed the administrative framework but did not remove the obligation to demonstrate GMP compliance.

Three principles are particularly important.

GMP compliance is continuous. Manufacturers must maintain compliance with applicable GMP requirements throughout their operations. The absence of a separate GMP certificate does not constitute an exemption from inspection.

Inspection findings can lead to regulatory action. CFDI analyses inspection risks, prepares conclusions and proposes handling measures. Administrative enforcement is exercised by the competent regulatory authorities within their respective jurisdictions.

MAH responsibility extends beyond the manufacturing site. The holder remains accountable for the quality of its products and must maintain effective oversight of contract manufacturers and other relevant organisations.

This model makes the MAH’s quality management and supplier oversight systems important elements of regulatory inspection.

International recognition and the export framework

ICH participation

NMPA joined ICH in 2017 and has participated in its Management Committee since 2018, with re-elections in 2021 and 2024.

This participation supports the alignment of Chinese drug development and registration requirements with internationally harmonised technical standards.

PIC/S application

NMPA submitted its formal application to the Pharmaceutical Inspection Co-operation Scheme (PIC/S) on 22 September 2023. In November 2023, PIC/S granted NMPA Applicant status.

Applicant status is an important step in the process, but it does not mean that China has become a full PIC/S member.

Cooperation with the European Union

China and the European Union have maintained a consultation and cooperation mechanism in the pharmaceutical field since 2010.

The European Medicines Agency (EMA) participates in this cooperation, which includes support for the development of GMP and Good Clinical Practice (GCP) standards and the exchange of inspection experience.

This cooperation mechanism should not be confused with a mutual recognition agreement for GMP inspections.

Export certificates: changes from 2026

NMPA issued the Administrative Provisions on Inspection and Export Certificate for Pharmaceutical Products Exported by Pharmaceutical Manufacturers (Announcement No. 113 of 2025). The provisions entered into force on 1 January 2026.

The new framework establishes requirements for inspection and export certification of pharmaceutical products manufactured for export.

Key provisions include:

  • manufacturers must maintain product dossiers for medicines intended for export;
  • inspections assess compliance with applicable GMP requirements;
  • export certificates identify the relevant pharmaceutical products or dosage forms and the inspection period;
  • the validity of the Certificate of a Pharmaceutical Product (CoPP) has been extended from two to three years;
  • provincial authorities are responsible for issuing the certificates under the new framework.

The provisions also establish a 20-working-day administrative processing limit for certificate issuance under the applicable procedures. This period does not include the time required for technical assessment, inspection or the correction of deficiencies.

The new framework strengthens the connection between export certification, product documentation and manufacturing-site compliance.

Checklist before an NMPA inspection

Companies planning to register or manufacture medicines for the Chinese market should consider the following points.

  1. Identify the regulatory pathway. Determine whether the site is domestic or overseas and which regulatory authority is responsible for its inspection.
  2. Confirm MAH responsibilities. Establish who holds the marketing authorisation and ensure that the relevant quality and regulatory responsibilities are clearly assigned.
  3. Identify the inspection type. Distinguish between registration inspections, pre-marketing GMP inspections, routine supervision, for-cause inspections and overseas inspections.
  4. Plan registration readiness. For registration inspections, account for the applicable 40-day completion requirement in the review timeline.
  5. Review material suppliers. Ensure that APIs, excipients and packaging materials meet the applicable registration and quality requirements. Check the associated review status in the NMPA database.
  6. Assess contract manufacturing oversight. Verify that supplier qualification, quality agreements, audits and ongoing supervision are properly implemented.
  7. Prepare for international regulatory interaction. Foreign manufacturers should ensure that their local representatives can support substantive regulatory communication and provide accurate technical documentation.
  8. Review export certification obligations. Manufacturers exporting pharmaceutical products from China should assess the requirements introduced by Announcement No. 113, effective from 1 January 2026.

China’s pharmaceutical inspection system is built around continuous compliance, risk-based supervision and lifecycle responsibility. For manufacturers supplying the Chinese market, understanding the division of responsibilities between NMPA, CDE, CFDI and provincial authorities is essential for effective regulatory planning and inspection readiness.

The next article in the Mapping Inspection Systems series examines India: CDSCO and inspections in the world’s largest generics manufacturing base.

POPULAR